Bio

Kevin Espinola combines more than two decades of experience with practical business judgment to advise companies and their boards of directors through a broad range of complex strategic corporate transactions. He also serves as primary outside counsel for public and private companies, particularly in the life sciences, technology, and software industries. Kevin has advised on M&A transactions with an aggregate value in excess of $150 billion. His M&A practice includes public company mergers and tender offers, private company acquisitions and divestitures, hostile takeovers, restructurings, recapitalizations, multifaceted cross-border transactions, and transactions involving contingent value rights and earn-outs. Kevin also regularly advises senior management teams and boards of directors in a wide range of corporate matters, including takeover preparedness, shareholder activism, stockholder proposals, SEC disclosure and reporting requirements, Nasdaq and NYSE compliance, and stock repurchase programs. He also counsels publicly held companies on the full range of governance issues, including board education, fiduciary duties, risk oversight, conflicts of interest, board and committee structure, board leadership, board audits and self-evaluation processes, and governance "best practices." Kevin recently served as lead outside counsel in a high-profile matter advising ICANN on governance and accountability reforms and mechanisms in connection with the transition of oversight of ICANN and its administration of the internet domain name system from the U.S. government to a multi-stakeholder community. Kevin's current and recent prior representations include Advantage Solutions, Ambry Genetics, Astellas Pharma, BioMarin, Celgene, Cylance, Epicor Software, Monolithic Power Systems, Oclaro, OneStream Software, Playtika, SAP, Suez, and TDK.